Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status

The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing an...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2017-09, Vol.14 (3), p.3817-3824
Main Authors: Kang, Ho Won, Kim, Ye-Hwan, Jeong, Pildu, Park, Cheol, Kim, Won Tae, Ryu, Dong Hee, Cha, Eun-Jong, Ha, Yun-Sok, Kim, Tae-Hwan, Kwon, Tae Gyun, Moon, Sung-Kwon, Choi, Yung Hyun, Yun, Seok-Joong, Kim, Wun-Jae
Format: Article
Language:English
Subjects:
Bladder cancer
Care and treatment
Clinical medicine
Development and progression
expression
Females
fibroblast growth factor receptor 3
Fibroblast growth factor receptors
Fibroblasts
Gender
Gene expression
Gene mutation
Genetic aspects
Growth factors
Health aspects
Kinases
Medical prognosis
Metastasis
Multivariate analysis
Mutation
Oncology
Patients
prognosis
Rodents
Standard deviation
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3
cites cdi_FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3
container_end_page 3824
container_issue 3
container_start_page 3817
container_title Oncology letters
container_volume 14
creator Kang, Ho Won
Kim, Ye-Hwan
Jeong, Pildu
Park, Cheol
Kim, Won Tae
Ryu, Dong Hee
Cha, Eun-Jong
Ha, Yun-Sok
Kim, Tae-Hwan
Kwon, Tae Gyun
Moon, Sung-Kwon
Choi, Yung Hyun
Yun, Seok-Joong
Kim, Wun-Jae
description The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P
doi_str_mv 10.3892/ol.2017.6621
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5587943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A511212966</galeid><sourcerecordid>A511212966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpjTOyBEIc2MUfcRJfkKqqW5BWqoTK2fLazq6LNw6epMB_4Ecz6W6XFuE5jD-e97U8nqJ4yehcNIp_SHHOKavnVcXZk-KY1YrPGG3408O8Lo-KU4AbikNWrGmq58URR23NJD8ufl_87LMHCKkj0d_6CCS1ZHG5-CKIAWJIn9O6SzAES7Ymf_OZtCmTYePvTu6lqOlzQOAX6a8ZWUXjHKLWdBaT6RwJA7oBJBvMMCl-hGFDtuOwWwHmEV4Uz1oTwZ_u80nxdXFxff5ptry6_Hx-tpxZKdQwE2YlJW0bUUrnFW8oNaKyjPpGcFUqZ6pauKp1iLRMWK-co8Z53jjnpHBWnBQfd779uNp6Z303ZBP1_gU6maAfn3Rho9fpVkvZ1KoUaPBub5DT99HDoLcBrI_RdD6NoJkqGVUSi4zo63_QmzTmDp83UZzJspH8L7U20evQtQnvtZOpPpOMccZVVSE1_w-F4fw22NT5NuD-I8HbB4KNN3HYQIrjVHN4DL7fgTYngOzbQzEY1VOn6RT11Gl66jTEXz0s4AG-7ysE3uwA6PHzg0twYK6WM4px5_MHtPXamg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1942154852</pqid></control><display><type>article</type><title>Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status</title><source>PubMed Central</source><creator>Kang, Ho Won ; Kim, Ye-Hwan ; Jeong, Pildu ; Park, Cheol ; Kim, Won Tae ; Ryu, Dong Hee ; Cha, Eun-Jong ; Ha, Yun-Sok ; Kim, Tae-Hwan ; Kwon, Tae Gyun ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok-Joong ; Kim, Wun-Jae</creator><creatorcontrib>Kang, Ho Won ; Kim, Ye-Hwan ; Jeong, Pildu ; Park, Cheol ; Kim, Won Tae ; Ryu, Dong Hee ; Cha, Eun-Jong ; Ha, Yun-Sok ; Kim, Tae-Hwan ; Kwon, Tae Gyun ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok-Joong ; Kim, Wun-Jae</creatorcontrib><description>The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P&lt;0.001). Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P&lt;0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression. Stratification by exon site of FGFR3 mutations yielded significant differences in mRNA expression level. None of the patients with BC harboring FGFR3 mutations in exon 9 demonstrated disease progression. The mRNA expression level of the FGFR3 gene may be used to precisely identify subsets of patients with pT1 BC that have a relatively better prognosis. The prognostic influences of FGFR3 mutations may be modulated by the exon site of FGFR3 mutations.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2017.6621</identifier><identifier>PMID: 28927152</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Bladder cancer ; Care and treatment ; Clinical medicine ; Development and progression ; expression ; Females ; fibroblast growth factor receptor 3 ; Fibroblast growth factor receptors ; Fibroblasts ; Gender ; Gene expression ; Gene mutation ; Genetic aspects ; Growth factors ; Health aspects ; Kinases ; Medical prognosis ; Metastasis ; Multivariate analysis ; Mutation ; Oncology ; Patients ; prognosis ; Rodents ; Standard deviation ; Studies ; Tumors</subject><ispartof>Oncology letters, 2017-09, Vol.14 (3), p.3817-3824</ispartof><rights>Copyright © 2017, Spandidos Publications</rights><rights>COPYRIGHT 2017 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2017</rights><rights>Copyright © 2017, Spandidos Publications 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3</citedby><cites>FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587943/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587943/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28927152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Ho Won</creatorcontrib><creatorcontrib>Kim, Ye-Hwan</creatorcontrib><creatorcontrib>Jeong, Pildu</creatorcontrib><creatorcontrib>Park, Cheol</creatorcontrib><creatorcontrib>Kim, Won Tae</creatorcontrib><creatorcontrib>Ryu, Dong Hee</creatorcontrib><creatorcontrib>Cha, Eun-Jong</creatorcontrib><creatorcontrib>Ha, Yun-Sok</creatorcontrib><creatorcontrib>Kim, Tae-Hwan</creatorcontrib><creatorcontrib>Kwon, Tae Gyun</creatorcontrib><creatorcontrib>Moon, Sung-Kwon</creatorcontrib><creatorcontrib>Choi, Yung Hyun</creatorcontrib><creatorcontrib>Yun, Seok-Joong</creatorcontrib><creatorcontrib>Kim, Wun-Jae</creatorcontrib><title>Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P&lt;0.001). Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P&lt;0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression. Stratification by exon site of FGFR3 mutations yielded significant differences in mRNA expression level. None of the patients with BC harboring FGFR3 mutations in exon 9 demonstrated disease progression. The mRNA expression level of the FGFR3 gene may be used to precisely identify subsets of patients with pT1 BC that have a relatively better prognosis. The prognostic influences of FGFR3 mutations may be modulated by the exon site of FGFR3 mutations.</description><subject>Bladder cancer</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>Development and progression</subject><subject>expression</subject><subject>Females</subject><subject>fibroblast growth factor receptor 3</subject><subject>Fibroblast growth factor receptors</subject><subject>Fibroblasts</subject><subject>Gender</subject><subject>Gene expression</subject><subject>Gene mutation</subject><subject>Genetic aspects</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>prognosis</subject><subject>Rodents</subject><subject>Standard deviation</subject><subject>Studies</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNptkk1v1DAQhiMEolXpjTOyBEIc2MUfcRJfkKqqW5BWqoTK2fLazq6LNw6epMB_4Ecz6W6XFuE5jD-e97U8nqJ4yehcNIp_SHHOKavnVcXZk-KY1YrPGG3408O8Lo-KU4AbikNWrGmq58URR23NJD8ufl_87LMHCKkj0d_6CCS1ZHG5-CKIAWJIn9O6SzAES7Ymf_OZtCmTYePvTu6lqOlzQOAX6a8ZWUXjHKLWdBaT6RwJA7oBJBvMMCl-hGFDtuOwWwHmEV4Uz1oTwZ_u80nxdXFxff5ptry6_Hx-tpxZKdQwE2YlJW0bUUrnFW8oNaKyjPpGcFUqZ6pauKp1iLRMWK-co8Z53jjnpHBWnBQfd779uNp6Z303ZBP1_gU6maAfn3Rho9fpVkvZ1KoUaPBub5DT99HDoLcBrI_RdD6NoJkqGVUSi4zo63_QmzTmDp83UZzJspH8L7U20evQtQnvtZOpPpOMccZVVSE1_w-F4fw22NT5NuD-I8HbB4KNN3HYQIrjVHN4DL7fgTYngOzbQzEY1VOn6RT11Gl66jTEXz0s4AG-7ysE3uwA6PHzg0twYK6WM4px5_MHtPXamg</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Kang, Ho Won</creator><creator>Kim, Ye-Hwan</creator><creator>Jeong, Pildu</creator><creator>Park, Cheol</creator><creator>Kim, Won Tae</creator><creator>Ryu, Dong Hee</creator><creator>Cha, Eun-Jong</creator><creator>Ha, Yun-Sok</creator><creator>Kim, Tae-Hwan</creator><creator>Kwon, Tae Gyun</creator><creator>Moon, Sung-Kwon</creator><creator>Choi, Yung Hyun</creator><creator>Yun, Seok-Joong</creator><creator>Kim, Wun-Jae</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170901</creationdate><title>Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status</title><author>Kang, Ho Won ; Kim, Ye-Hwan ; Jeong, Pildu ; Park, Cheol ; Kim, Won Tae ; Ryu, Dong Hee ; Cha, Eun-Jong ; Ha, Yun-Sok ; Kim, Tae-Hwan ; Kwon, Tae Gyun ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok-Joong ; Kim, Wun-Jae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Bladder cancer</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>Development and progression</topic><topic>expression</topic><topic>Females</topic><topic>fibroblast growth factor receptor 3</topic><topic>Fibroblast growth factor receptors</topic><topic>Fibroblasts</topic><topic>Gender</topic><topic>Gene expression</topic><topic>Gene mutation</topic><topic>Genetic aspects</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>prognosis</topic><topic>Rodents</topic><topic>Standard deviation</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Ho Won</creatorcontrib><creatorcontrib>Kim, Ye-Hwan</creatorcontrib><creatorcontrib>Jeong, Pildu</creatorcontrib><creatorcontrib>Park, Cheol</creatorcontrib><creatorcontrib>Kim, Won Tae</creatorcontrib><creatorcontrib>Ryu, Dong Hee</creatorcontrib><creatorcontrib>Cha, Eun-Jong</creatorcontrib><creatorcontrib>Ha, Yun-Sok</creatorcontrib><creatorcontrib>Kim, Tae-Hwan</creatorcontrib><creatorcontrib>Kwon, Tae Gyun</creatorcontrib><creatorcontrib>Moon, Sung-Kwon</creatorcontrib><creatorcontrib>Choi, Yung Hyun</creatorcontrib><creatorcontrib>Yun, Seok-Joong</creatorcontrib><creatorcontrib>Kim, Wun-Jae</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Ho Won</au><au>Kim, Ye-Hwan</au><au>Jeong, Pildu</au><au>Park, Cheol</au><au>Kim, Won Tae</au><au>Ryu, Dong Hee</au><au>Cha, Eun-Jong</au><au>Ha, Yun-Sok</au><au>Kim, Tae-Hwan</au><au>Kwon, Tae Gyun</au><au>Moon, Sung-Kwon</au><au>Choi, Yung Hyun</au><au>Yun, Seok-Joong</au><au>Kim, Wun-Jae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>14</volume><issue>3</issue><spage>3817</spage><epage>3824</epage><pages>3817-3824</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The present study examined the utility of fibroblast growth factor receptor 3 (FGFR3) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). A total of 120 patients with primary pT1 BC were enrolled. FGFR3 mutation status was determined by direct sequencing and FGFR3 mRNA expression level was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The results were compared with the clinicopathological parameters, and the prognostic value of FGFR3 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression test. FGFR3 mutations were identified in 48/120 (40.0%) patients with pT1 BC. FGFR3 mRNA expression level was significantly higher in those with BC harboring FGFR3 mutations (P&lt;0.001). Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P&lt;0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression. Stratification by exon site of FGFR3 mutations yielded significant differences in mRNA expression level. None of the patients with BC harboring FGFR3 mutations in exon 9 demonstrated disease progression. The mRNA expression level of the FGFR3 gene may be used to precisely identify subsets of patients with pT1 BC that have a relatively better prognosis. The prognostic influences of FGFR3 mutations may be modulated by the exon site of FGFR3 mutations.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>28927152</pmid><doi>10.3892/ol.2017.6621</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2017-09, Vol.14 (3), p.3817-3824
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5587943
source PubMed Central
subjects Bladder cancer
Care and treatment
Clinical medicine
Development and progression
expression
Females
fibroblast growth factor receptor 3
Fibroblast growth factor receptors
Fibroblasts
Gender
Gene expression
Gene mutation
Genetic aspects
Growth factors
Health aspects
Kinases
Medical prognosis
Metastasis
Multivariate analysis
Mutation
Oncology
Patients
prognosis
Rodents
Standard deviation
Studies
Tumors
title Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A21%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20levels%20of%20FGFR3%20as%20a%20prognostic%20marker%20for%20the%20progression%20of%20primary%20pT1%20bladder%20cancer%20and%20its%20association%20with%20mutation%20status&rft.jtitle=Oncology%20letters&rft.au=Kang,%20Ho%20Won&rft.date=2017-09-01&rft.volume=14&rft.issue=3&rft.spage=3817&rft.epage=3824&rft.pages=3817-3824&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2017.6621&rft_dat=%3Cgale_pubme%3EA511212966%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c539t-3ab550f8345de92800a36c10e832949da673d6fd0f8f13ce9dd0ade28ddd53dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1942154852&rft_id=info:pmid/28927152&rft_galeid=A511212966&rfr_iscdi=true